Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas

被引:239
作者
George, Suzanne [1 ]
Merriam, Priscilla
Maki, Robert G.
Van den Abbeele, Annick D.
Yap, Jeffrey T.
Akhurst, Timothy
Harmon, David C.
Bhuchar, Gauri
O'Mara, Margaret M.
D'Adamo, David R.
Morgan, Jeffrey
Schwartz, Gary K.
Wagner, Andrew J.
Butrynski, James E.
Demetri, George D.
Keohan, Mary L.
机构
[1] Massachusetts Gen Hosp, Ctr Sarcoma & Bone Oncol, Dana Farber Canc Inst, Dana Farber Harvard Canc Ctr,Ludwig Ctr, Boston, MA 02115 USA
关键词
POSITRON-EMISSION-TOMOGRAPHY; IMATINIB MESYLATE; CARCINOMA; EFFICACY; THERAPY; TARGETS;
D O I
10.1200/JCO.2008.20.9890
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose To evaluate the potential benefit of continuous daily dosing sunitinib in patients with advanced nongastrointestinal stromal tumor (GIST) sarcomas. Patients and Methods A total of 53 patients with advanced non-GIST soft tissue sarcomas received sunitinib 37.5 mg daily. Primary end point was Response Evaluation Criteria in Solid Tumors defined response. Secondary end points were stable disease at 16 and 24 weeks. [F-18]-fluorodeoxyglucose positron emission tomography was performed on a subset of 24 patients at baseline and after 10 to 14 days of therapy. Results Forty-eight patients were eligible for response. One patient (desmoplastic round cell tumor [DSRCT]) achieved a confirmed partial response (PR) and remained on study for 56 weeks. Ten patients (20%) achieved stable disease for at least 16 weeks. Metabolic PR was seen in 10 (47%) of 21 of patients. Metabolic stable disease was seen in 11 (52%) of 21. There were no unexpected toxicities observed. Conclusion Sunitinib demonstrated notable evidence of metabolic response in several patients with non-GIST sarcoma. The relevance of disease control observed in subtypes with an indolent natural history is unknown, however, the durable disease control observed in DSRCT, solitary fibrous tumor, and giant cell tumor of bone suggests that future evaluation of sunitinib in these subtypes may be warranted.
引用
收藏
页码:3154 / 3160
页数:7
相关论文
共 40 条
[31]  
SLEIJFER S, 2007, CONN TISS ONC SOC 13
[32]   18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec®) [J].
Stroobants, S ;
Goeminne, J ;
Seegers, M ;
Dimitrijevic, S ;
Dupont, P ;
Nuyts, J ;
Martens, M ;
van den Borne, B ;
Cole, P ;
Sciot, R ;
Dumez, H ;
Silberman, S ;
Mortelmans, L ;
van Oosterom, A .
EUROPEAN JOURNAL OF CANCER, 2003, 39 (14) :2012-2020
[33]   Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas [J].
Tamborini, E. ;
Casieri, P. ;
Miselli, F. ;
Orsenigo, M. ;
Negri, T. ;
Piacenza, C. ;
Stacchiotti, S. ;
Gronchi, A. ;
Pastorino, U. ;
Pierotti, M. A. ;
Pilotti, S. .
JOURNAL OF PATHOLOGY, 2007, 212 (02) :227-235
[34]   Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas [J].
Tamborini, Elena ;
Miselli, Francesca ;
Negri, Tiziana ;
Lagonigro, M. Stefania ;
Staurengo, Samantha ;
Dagrada, Gian Paolo ;
Stacchiotti, Silvia ;
Pastore, Elisa ;
Gronchi, Alessandro ;
Perrone, Federica ;
Carbone, Antonino ;
Pierotti, Marco A. ;
Casali, Paolo G. ;
Pilotti, Silvana .
CLINICAL CANCER RESEARCH, 2006, 12 (23) :6920-6928
[35]  
Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205
[36]   Signal transduction pathways in sarcoma as targets for therapeutic intervention [J].
Tuveson, DA ;
Fletcher, JA .
CURRENT OPINION IN ONCOLOGY, 2001, 13 (04) :249-255
[37]  
van den Abbeele A, 2005, J CLIN ONCOL, V23, p817S
[38]  
Van den Abbeele AD, 2001, P AN M AM SOC CLIN, V20, p362a
[39]   Genetic aberrations in soft tissue leiomyosarcoma [J].
Yang, Jilong ;
Du, Xiaoling ;
Chen, Kexin ;
Ylipaeae, Antti ;
Lazar, Alexander J. F. ;
Trent, Jonathan ;
Lev, Dina ;
Pollock, Raphael ;
Hao, Xishan ;
Hunt, Kelly ;
Zhang, Wei .
CANCER LETTERS, 2009, 275 (01) :1-8
[40]   Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography:: Review and 1999 EORTC recommendations [J].
Young, H ;
Baum, R ;
Cremerius, U ;
Herholz, K ;
Hoekstra, O ;
Lammertsma, AA ;
Pruim, J ;
Price, P .
EUROPEAN JOURNAL OF CANCER, 1999, 35 (13) :1773-1782